Form 8-K Axovant Sciences Ltd. For: Aug 15

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/16/2026

1. VRNS
2. JBHT
3. CRWV
4. SCHW
5. GPRK
6. TFC
7. NEST:IN
8. AA
9. TECHM:IN
10. TSLA

Go back to Form 8-K Axovant Sciences Ltd. For: Aug 15

Axovant Sciences (AXON) Misses Q1 EPS by 2c; Enters Licensing Agreement with Qaam Pharma

August 16, 2016 7:24 AM EDT

Axovant Sciences (NYSE: AXON) reported Q1 EPS of ($0.38), $0.02 worse than the analyst estimate of ($0.36).

sAxovant and Qaam Pharmaceuticals (Qaam) have entered into an exclusive license agreement under which Axovant expects to develop and, if successful, commercialize products that combine cholinesterase inhibitors with peripheral muscarinic receptor antagonists including glycopyrrolate, which could mitigate the peripheral side effects of cholinesterase inhibitors. Axovant will initially develop RVT-103, a combination of glycopyrrolate and donepezil. In addition, Axovant expects to develop RVT-104, a combination of glycopyrrolate and high-dose rivastigmine. Axovant believes that the intellectual property portfolio licensed... More